Bill > SR53

This resolution celebrates the University of Kentucky Markey Cancer Center for its significant scientific advancements, specifically highlighting its role as the first institution in the United States to treat a patient with a new immunotherapy for small cell lung cancer. This experimental drug, ZG006 (Alveltamig), works by activating the body's T cells, a type of immune cell, to attack cancer cells, offering a new hope for patients whose cancers have become resistant to traditional treatments. The Markey Cancer Center, recognized as a National Cancer Institute-designated Comprehensive Cancer Center, is leading a clinical trial for this drug, which addresses a critical need for patients with advanced small cell lung cancer, a disease often diagnosed late. The resolution notes the successful initial treatment of a patient with no side effects, and the potential for this immunotherapy to effectively treat brain metastases, a common complication of this cancer, thereby potentially reducing the need for radiation therapy and its associated side effects.

https://apps.legislature.ky.gov/record/26RS/sr53.html